KRAS and neoplasm: It has been proven that the inhibition of phosphorylated ERK1/2 level in tumor cells with KRAS mutations may cause wide-type RAF phosphorylation and further result in activation of MEK, thereby restoring pERK level quickly and acquiring rebound.